Apogee Opportunities

Apogee Therapeutics is a clinical-stage biotechnology company focused on developing differentiated biologics for the treatment of atopic dermatitis, asthma, and other inflammatory and immunology (I&I) diseases. The company leverages advanced antibody engineering to create therapies with improved half-lives and potency compared to existing standards of care. Its lead program, APG777, is a subcutaneous monoclonal antibody targeting IL-13 designed for extended dosing intervals, potentially offering every-three-month or every-six-month maintenance schedules. Apogee aims to address significant unmet needs in the multi-billion dollar I&I market by optimizing established biological pathways.